Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

A women with hand osteoarthritis rubs her hands together

Hand osteoarthritis affects more than two million people in the UK. There are few evidence-based interventions to treat the condition, other than pain relief and exercise, which are often inadequate. The NIHR-funded HOPE-e study is recruiting post-menopausal women to see whether painful osteoarthritis in joints of their hands can be treated with hormone replacement therapy (HRT).

The study is currently recruiting women aged 40 to 65 years old who are between one and 10 years after their menopause. Participants will take either a type of HRT tablet or a placebo (inactive tablet) for 24 weeks.

Like many research studies during the Coronavirus pandemic, the HOPE-e study paused recruitment on 16 March 2020, but were delighted to be able to restart the study from the end of August at various sites including the Nuffield Orthopaedic Centre, part of Oxford University Hospitals NHS Foundation Trust in Oxford.

The study team has made several modifications to the study to allow it to run in the new COVID-secure era. Four of the five study visits are now typically carried out remotely over the telephone with only the first screening visit requiring a face-to-face visit to the clinic.

Professor Fiona Watt, HOPE-e Chief Investigator, based at University of Oxford's Kennedy Institute of Rheumatology, says "With all bar one of the study visits now possible remotely, COVID has taught us how much we can do by phone and online. 

"Just like the NHS, research needs to be flexible and change to new models where we can, whilst making sure everyone stays safe. Ultimately, we hope this 'new look' may also prove popular with women who work, have busy lives or live further away who have painful hand osteoarthritis and want to take part in the study."

The study is recruiting participants until the end of December 2020.

More information on taking part can be found on the HOPE-e website.

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

AVID-CC trial opens to recruitment!

OCTRU

The AVID-CC trial has received OCTRU Green Light approval and is now open to recruitment!

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.